Movement disorders and chronic psychosis

Neurology: Clinical Practice

Volumn 7, Issue 2, 2017, Pages 163-169

  Martino, Davide ^a   Morgante, Francesca ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MESSINA   (Italy)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DOPAMINE TRANSPORTER; LEVODOPA; NEUROLEPTIC AGENT; VESICULAR MONOAMINE TRANSPORTER 2;

ADOLESCENCE; BRAIN DEPTH STIMULATION; CHILDHOOD; CHOREA; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GLOBUS PALLIDUS; HIGH RISK PATIENT; HUMAN; HYPERKINESIA; HYPOKINESIA; LONGITUDINAL STUDY; MOTOR DYSFUNCTION; NEUROIMAGING; PARKINSONISM; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTYPY; TARDIVE DYSKINESIA;

EID: 85017367415     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0000000000000344     Document Type: Review

References (27)

1. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-Treatments meta-Analysis. Lancet 2013; 382: 951-962.
2. Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry 2007; 191: 238-245.
3. Etminan M, Procyshyn RM, Samii A, Carleton BC. Risk of extrapyramidal adverse events with aripiprazole. J Clin Psychopharmacol 2016; 36: 472-474.
4. Carbon M, Kapoor S, Sheridan E, et al. Neuromotor adverse effects in 342 youth during 12 weeks of naturalistic treatment with 5 second-generation antipsychotics. J Am Acad Child Adolesc Psychiatry 2015; 54: 718-727.
5. Thomas JE, Caballero J, Harrington CA. The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-Analysis. Curr Neuropharmacol 2015; 13: 681-691.
6. Bernagie C, Danckaerts M, Wampers M, De Hert M. Aripiprazole and acute extrapyramidal symptoms in children and adolescents: a meta-Analysis. CNS Drugs 2016; 30: 807-818.
7. Tinazzi M, Ottaviani S, Isaias IU, et al. [123I]FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord 2008; 23: 1825-1829.
8. Tinazzi M, Morgante F, Matinella A, et al. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Schizophr Res 2014; 152: 344-349.
9. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993; 33: 512-517.
10. Park J, Chung S, An H, et al. Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons. Neuroscience 2012; 209: 64-73.
11. Butcher NJ, Kiehl TR, Hazrati LN, et al. Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol 2013; 70: 1359-1366.
12. Shuaib UA, Rajput AH, Robinson CA, Rajput A. Neuroleptic-induced parkinsonism: clinicopathological study. Mov Disord 2016; 31: 360-365.
13. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81: 463-469.
14. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs 2016; 76: 779-787.
15. O?Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transporter inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 2015; 30: 1681-1687.
16. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 2016; 17: 2461-2470.
17. Muller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs 2015; 24: 737-742.
18. Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord 2014; 20(suppl 1): S113-S117.
19. Eltahawy HA, Feinstein A, Khan F, Saint-Cyr J, Lang AE, Lozano AM. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord 2004; 19: 969-972.
20. Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007; 64: 170-176.
21. Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-Term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 2016; 86: 651-659.
22. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with firstepisode psychoses: a systematic review. Psychol Med 2009; 39: 1065-1076.
23. Walther S, Ramseyer F, Horn H, Strik W, Tschacher W. Less structured movement patterns predict severity of positive syndrome, excitement, and disorganization. Schizophr Bull 2014; 40: 585-591.
24. Mittal VA, Walker EF, Bearden CE, et al. Markers of basal ganglia dysfunction and conversion to psychosis: neurocognitive deficits and dyskinesias in the prodromal period. Biol Psychiatry 2010; 68: 93-99.
25. Kindler J, Schultze-Lutter F, Michel C, et al. Abnormal involuntary movements are linked to psychosis-risk in children and adolescents: results of a population-based study. Schizophr Res 2016; 174: 58-64.
26. Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187-193.
27. Garay RP, Bourin M, de Paillette E, Samalin L, Hameg A, Llorca PM. Potential serotonergic agents for the treatment of schizophrenia. Expert Opin Investig Drugs 2016; 25: 159-170.